Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Advances in immunotherapy for lymphoma

Martin Hutchings • 12 Dec 2021
ASH 2021
Lymphoma Antibodies CAR-T

Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, provides an overview of current developments in the field of immunotherapy in lymphoma. A lot of progress has been made in monoclonal antibodies, bispecific antibodies, as well as chimeric antigen receptor (CAR) T-cell therapies. Dr Hutchings additionally comments on looking forward to the next generation of immunotherapies, such as anti-CD20 IgM antibodies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Martin Hutchings

2:54
Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL
Martin Hutchings • 10 Dec 2023
3:58
Extended follow-up of glofitamab monotherapy in R/R LBCL: durability of CR and likelihood of CRS
Martin Hutchings • 10 Dec 2023
Bispecific antibodies in NHL
Krish Patel et al. • 17 Oct 2023
1:32
Assessing the dynamics of CD8-expressing cells in patients with R/R LBCL treated with glofitamab
Martin Hutchings • 11 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals